Virax Biolabs Group Limited (VRAX)

Market Cap	10.65M
Revenue (ttm)	5,760
Net Income (ttm)	-2.60M
Shares Out	12.83M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,544
Open	0.820
Previous Close	0.820
Day's Range	0.800 - 0.840
52-Week Range	0.540 - 29.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About VRAX

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared the...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 21, 2022
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: VRAX